Noxopharm (ASX:NOX) has made some changes to its senior executive and Board structures.
Dr Gisela Mautner has been promoted from Global Medical Director to Chief Medical Officer, responsible for the Company’s clinical trial activities and strategy.
Dr John Wilkinson remains as Chief Scientific Officer but will have a focus on supporting the Veyonda? clinical program.
Dr Olivier Laczka has been appointed as Director of Drug Discovery and Research and is charged with growing the Company’s drug pipeline, with four programs currently underway.
US operations Greg Ambra has been appointed as Senior Vice-President North American Operations.
His role will be to oversee the growth of the Company’s North American clinical trial program and to grow the Company’s presence and profile within the investment community and pharmaceutical industry.
Shares in Noxopharm (ASX: NOX) trading 1.35 per cent higher at 38 cents.